Zymeworks agrees to buy Theravance Biopharma for $929m

Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m. The boards of both companies unanimously approved the agreement, which remains subject to shareholder and regulatory approvals. Zymeworks will be entitled to 20% of the proceeds from ampreloxetine. Credit: JHVEPhoto/Shutterstock.com. Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn). Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. NPVM: Dyne Therapeutics Inc's DYNE-251 Reports NPVM: Tenaya Therapeutics Inc's TN-301 Go deeper with GlobalData The gold standard…

Salong Debbarma · 2026-06-30

Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m.

Source: Pharmaceutical Technology